VivoSeq
Other

Hormone Therapy

0

Pipeline Programs↗

7

Active Trials↗

1

Companies Involved↗

Hormone Therapy is an early-stage landscape with 0 programs across 1 company. The most active players are Bayer.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

63/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

18

clinical trials

Recruiting7 · 39%
Completed5 · 28%
Unknown status3 · 17%
Terminated2 · 11%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

18 trials

China Gender-affirming Hormone Therapy Study
Recruiting·PPeking University Third Hospital·N/A·NCT05318755·240 enrolled
Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content
Recruiting·MMedical University of Vienna·N/A·NCT06291675·50 enrolled
Progesterone in Gender Affirming Hormone Therapy Study
Recruiting·EEmory University·Phase 2·NCT06807580·40 enrolled
Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy
Recruiting·—·Phase 3·NCT05586724·520 enrolled
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Recruiting·SStanford University·Phase 1/2·NCT05891795·18 enrolled
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT06832774·192 enrolled
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Recruiting·NNational Taiwan University Hospital·Phase 2·NCT05720260·42 enrolled
Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy
Completed·UUniversity of California, San Francisco·Phase 4·NCT04050371·48 enrolled
Effect of Menopausal Hormone Therapy on Immune System Parameters
Completed·Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare·Phase 1·NCT05678192·40 enrolled
Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women
Completed·EEmory University·N/A·NCT04531943·285 enrolled
Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy
Completed·FFederal University of São Paulo·N/A·NCT01016665·71 enrolled
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
Completed·Bayer logoBayer·N/A·NCT03896984·346 enrolled
Effect of Gender Affirming Hormone Therapy on Glucose Metabolism
Terminated·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT04515472·24 enrolled
Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers
Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00236301·99 enrolled
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
Withdrawn·YYale University·Phase 1·NCT04922424
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)